Shik Luen Paul Ip

Array ( [id] => 17336036 [patent_doc_number] => 20220002367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/478600 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753981 [patent_doc_number] => 20230357338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => FACTOR H FRAGMENT Fc FUSIONS WITH IMPROVED POTENCY AND MANUFACTURABILITY [patent_app_type] => utility [patent_app_number] => 18/245453 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314500 [patent_doc_number] => 20210403548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/471702 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290985 [patent_doc_number] => 20210386824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => Nucleic Acids Encoding FGF21-Fc Fusion Proteins [patent_app_type] => utility [patent_app_number] => 17/410307 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17387058 [patent_doc_number] => 20220034910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/403078 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753978 [patent_doc_number] => 20230357334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => COMPOSITION OF DRUG AND WILD-TYPE CELL-PENETRATING PEPTIDE DERIVATIVE [patent_app_type] => utility [patent_app_number] => 18/021868 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18650795 [patent_doc_number] => 20230296630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE [patent_app_type] => utility [patent_app_number] => 18/021021 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18727122 [patent_doc_number] => 20230341403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER [patent_app_type] => utility [patent_app_number] => 18/005082 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343698 [patent_doc_number] => 20220010029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => HYBRIDOMA CELL STRAIN THAT SECRETS ANTI-DINITOLMIDE MONOCLONAL ANTIBODIES AND THE APPLICATION OF HYBRIDOMA CELL STRAIN [patent_app_type] => utility [patent_app_number] => 17/368108 [patent_app_country] => US [patent_app_date] => 2021-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17368108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343690 [patent_doc_number] => 20220010021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides [patent_app_type] => utility [patent_app_number] => 17/365183 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 552 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156125 [patent_doc_number] => 20210317176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => FG21 MUTANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/357444 [patent_app_country] => US [patent_app_date] => 2021-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480636 [patent_doc_number] => 20220088140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Metabolic Disorders and Diseases [patent_app_type] => utility [patent_app_number] => 17/356070 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497452 [patent_doc_number] => 20230220088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods [patent_app_type] => utility [patent_app_number] => 18/002066 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412771 [patent_doc_number] => 20220047675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING PEPTIDE VARIANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/355002 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336066 [patent_doc_number] => 20220002397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHOD FOR IMPROVING INHIBITION OF VEGF-BINDING TO VEGF-R1 OF AN ANTI-VEGF ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/350273 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443826 [patent_doc_number] => 20220064331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/341990 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17341990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548172 [patent_doc_number] => 20220119513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => ANTI-TGFB ANTIBODIES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/341212 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -134 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17341212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399613 [patent_doc_number] => 20220041703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM NON-IG SCAFFOLD FOR USE IN INTERVENTION AND THERAPY OF CONGESTION IN A PATIENT IN NEED THEREOF [patent_app_type] => utility [patent_app_number] => 17/339221 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228627 [patent_doc_number] => 20210355183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/332062 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359337 [patent_doc_number] => 20240261371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 17/999903 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999903 [rel_patent_id] =>[rel_patent_doc_number] =>)